Skip to content

Depression: all studies

Page 751 of 1,034: studies 7,501 to 7,510 of 10,336, newest first. Back to the depression overview

Research

Brain entropy, fractal dimensions and predictability: A review of complexity measures for EEG in healthy and neuropsychiatric populations

European Journal of Neuroscience August 19, 2022 Zen Juen Lau, Tam Pham, Shen‐hsing Annabel Chen et al. 225 citations

Abstract There has been an increasing trend towards the use of complexity analysis in quantifying neural activity measured by electroencephalography (EEG) signals. On top of revealing complex neuronal processes of the brain that may not be possible with linear approaches, EEG complexity measures have also demonstrated their potential as biomarkers of psychopathology such as depression and...

DOI: 10.1111/ejn.15800 (opens in new tab) Anxiety Electroencephalography Predictability Cognitive psychology +3

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in Gymnopilus dilepis Mushroom via Amino Acid Metabolism Pathways

Journal of Fungi August 18, 2022 Sen Yao, Chuanzheng Wei, Hui Lin et al. 6 citations

As a potential medicine for the treatment of depression, psilocybin has gradually attracted attention. To elucidate the molecular mechanism regulating psilocybin synthesis in Gymnopilus dilepis, ultra-performance liquid chromatography (UPLC) was used to detect the changes in psilocybin content after S-adenosyl-l-homocysteine (SAH) treatment and the changes of psilocybin content in different...

DOI: 10.3390/jof8080870 (opens in new tab) Psilocybin Stipe mycology Biochemistry Cysteine +3

A-118 Psychedelic Interventions for Neuropsychological Conditions

Archives of Clinical Neuropsychology August 17, 2022 Brian Peacock 3 citations

Abstract Objective: Psychedelic-assisted therapies are emerging as safe and effective treatments for some psychological conditions including depression, anxiety, posttraumatic stress disorder, and substance use disorders. As ketamine therapy is already available in general medicine and 3,4 Methylenedioxymethamphetamine (MDMA) and psilocybin are in late-stage clinical trials, neuropsychologists...

Arketamine, a new rapid-acting antidepressant: A historical review and future directions

Neuropharmacology August 14, 2022 Ji-Chun Zhang, Wei Yao, Kenji Hashimoto 88 citations

The N-methyl-d-aspartate receptor (NMDAR) antagonist (R,S)-ketamine causes rapid onset and sustained antidepressant actions in treatment-resistant patients with major depressive disorder (MDD) and other psychiatric disorders, such as bipolar disorder and post-traumatic stress disorder. (R,S)-ketamine is a racemic mixture consisting of (R)-ketamine (or arketamine) and (S)-ketamine (or...

DOI: 10.1016/j.neuropharm.2022.109219 (opens in new tab) Antidepressant Psychotherapist Pharmacology

The effect of mindfulness-based cognitive therapy on rumination and a task-based measure of intrusive thoughts in patients with bipolar disorder.

International Journal of Bipolar Disorders August 12, 2022 Jelle Lubbers, Dirk E. M. Geurts, Imke Hanssen et al.

Preliminary evidence suggests that Mindfulness-Based Cognitive Therapy (MBCT) is a promising treatment for bipolar disorder (BD). A proposed working mechanism of MBCT in attenuating depressive symptoms is reducing depressive rumination. The primary aim of this study was to investigate the effect of MBCT on self-reported trait depressive rumination and an experimental state measure of negative...

DOI: 10.1186/s40345-022-00269-1 (opens in new tab) Full text (opens in new tab) Bipolar disorder Breathing focus task Depressive rumination Intrusive thoughts +2

Effectiveness, Acceptability, and Mechanisms of Change of the Internet-Based Intervention StudiCare Mindfulness for College Students: a Randomized Controlled Trial

Mindfulness August 10, 2022 Ann-Marie Küchler, Fanny Kählke, Danielle Vollbrecht et al. 30 citations

Abstract Objectives College is an exhilarating but stressful time often associated with mental distress. The StudiCare project offers Internet- and mobile-based interventions (IMI) for college student mental health promotion. Within this framework, we evaluated the IMI StudiCare Mindfulness, and examined potential moderators and mediators of effectiveness. Methods In this randomized controlled...

Safety and efficacy of ketamine-augmented electroconvulsive therapy in third trimester pregnancy complicated by COVID-19

Proceedings August 8, 2022 Ashmi Patel, Anna Saucier, C. Hobday et al.

Abstract Major depressive disorder during pregnancy can be detrimental to the fetus and patient. Treatments can include electroconvulsive therapy (ECT) for severe cases. The use of ketamine in ECT can provide symptomatic relief as well as induce anesthesia. Here, we describe the case of a 35-year-old gravid woman with a long-standing history of major depressive disorder who presented with...

The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world

Psychopharmacology August 8, 2022 Rosalind Watts, Hannes Kettner, Dana Geerts et al. 159 citations

Abstract Rationale A general feeling of disconnection has been associated with mental and emotional suffering. Improvements to a sense of connectedness to self, others and the wider world have been reported by participants in clinical trials of psychedelic therapy. Such accounts have led us to a definition of the psychological construct of ‘connectedness’ as ‘a state of feeling connected to...

Psychiatry organization does not endorse psychedelic treatment

Alcoholism & Drug Abuse Weekly August 5, 2022 A. Knopf

Last month the American Psychiatric Association (APA) issued a position statement on psychedelics warning about the short‐ and long‐term risks of these unapproved drugs. Sanctioned by the APA board of trustees, the “Position Statement on the Use of Psychedelic and Empathogenic Agents for Mental Health Conditions” notes that preliminary research involving psychedelics for the treatment of...

AXS-05: an investigational treatment for Alzheimer's disease-associated agitation.

Expert Opinion on Investigational Drugs August 2022 Kristen Ward, Leslie Citrome

Agitation is common in patients with Alzheimer's disease (AD). Although nonpharmacologic de-escalation strategies are recommended as first-line treatment, medication is often needed to treat agitation. Currently, there are no FDA-approved medications for this indication. Psychotropics used to treat agitation include antipsychotics, which are notable for their efficacy but also their potential...

DOI: 10.1080/13543784.2022.2096006 (opens in new tab) Full text (opens in new tab) Agitation Alzheimer’s disease Aggression Bupropion +3